Beranda › Sindrom Down › Florida › Orlando
Uji klinis Sindrom Down di Orlando, FL
5 studi untuk Sindrom Down mencari peserta di lokasi sekitar Orlando (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Menerima pesertaFase 2
- Clinical Study Site, Maitland · 6 mi jauhnya
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- AdventHealth Orlando, Orlando
- Arnold Palmer Hospital for Children, Orlando
- Nemours Children's Hospital, Orlando
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Menerima pesertaStudi observasional
- Nemours Children's Hospital, Orlando
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Menerima pesertaFase 1/2
- Charter Research, LLC, Orlando
- Headlands Horizons LLC, Orlando
Measuring Aided Language Development
Menerima peserta
- University of Central Florida - Innovative Center, Orlando
Uji klinis Sindrom Down di kota lain
- Aurora, CO7 studi
- Houston, TX6 studi
- Phoenix, AZ6 studi
- Durham, NC6 studi
- Cincinnati, OH5 studi
- Nashville, TN5 studi
- Kansas City, KS5 studi
- Ann Arbor, MI5 studi
- Cleveland, OH5 studi
- Philadelphia, PA5 studi
- Atlanta, GA4 studi
- Birmingham, AL4 studi
Studi lain di Orlando
- Kanker Paru Non-Sel Kecil44 studi
- Obesitas31 studi
- Kanker Metastatik29 studi
- Kelebihan Berat Badan27 studi
- Penyakit Alzheimer25 studi
- Diabetes Tipe 224 studi
- Kanker (semua jenis)24 studi
- Kanker Payudara23 studi
- Kanker Ovarium22 studi
- Kolitis Ulseratif22 studi
- Kanker Paru21 studi
- Kanker Kolorektal19 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.